Ironwood Pharmaceuticals traded at $11.82 this Wednesday August 10th, decreasing $0.02 or 0.17 percent since the previous trading session. Looking back, over the last four weeks, Ironwood Pharmaceuticals lost 1.01 percent. Over the last 12 months, its price fell by 15.09 percent. Looking ahead, we forecast Ironwood Pharmaceuticals to be priced at 11.54 by the end of this quarter and at 10.61 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,782.00 34.00 0.91% 2.97%
Astellas Pharma 2,014.50 -29.00 -1.42% 11.73%
Acadia Pharmaceuticals 16.15 -0.07 -0.43% -11.89%
Agios Pharmaceuticals 28.22 0.85 3.11% -35.70%
Akebia Therapeutics 0.42 0.01 2.77% -83.82%
Almirall SA 9.85 0.05 0.51% -28.92%
Alnylam Pharmaceuticals 232.00 8.63 3.86% 14.37%
Amarin 1.53 0.12 8.51% -68.97%
Ardelyx 0.91 0.03 3.48% -39.74%
AstraZeneca 10,690.00 -128.00 -1.18% 28.81%
Astrazeneca 66.30 0.41 0.62% 17.12%
Bluebird Bio 5.93 0.43 7.82% -68.89%
Coherus Biosciences 12.97 1.91 17.27% -2.92%
Charles River Laboratories 226.52 12.04 5.61% -43.27%
Emergent BioSolutions 30.50 0.78 2.62% -49.55%
Esperion Therapeutics 6.41 -0.02 -0.31% -54.47%
Exact Sciences 45.13 2.08 4.83% -53.08%
Halozyme Therapeutics 44.10 0.77 1.78% 8.22%
Intercept Pharmaceuticals 16.70 0.04 0.24% 9.36%
Incyte Corp 74.13 0.40 0.54% 1.69%
Ironwood Pharmaceuticals 11.82 -0.02 -0.17% -15.09%
Karyopharm Therapeutics 5.20 0.29 5.91% -0.57%
Lexicon Pharmaceuticals 2.78 0.22 8.59% -24.46%
MacroGenics 4.98 -0.12 -2.35% -79.84%
Moderna Inc 174.27 3.13 1.83% -54.77%
Myriad Genetics 27.47 1.27 4.85% -15.42%
Puma Biotechnology 3.57 -0.08 -2.19% -50.49%
Pacira 57.21 -1.11 -1.90% 0.67%
PTC Therapeutics 53.71 1.99 3.85% 33.54%
Ultragenyx Pharmaceutical 52.16 0.79 1.54% -43.76%
Sarepta Therapeutics 113.07 3.97 3.64% 39.78%
Vanda Pharmaceuticals 10.55 0.28 2.73% -34.72%

Indexes Price Day Year
USND 12855 360.88 2.89% -12.94%
US2000 1969 56.36 2.95% -12.49%

Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company. The Company is focused on the development and commercialization of GI product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC). It operates in human therapeutics business segment. Its product candidate LINZESS (linaclotide) is available to adult men and women suffering from IBS-C or CIC in the United States, and Mexico and to adult men and women suffering from IBS-C in Japan and China. Its linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries.